Breast cancer control programme in developing countries (1994)
- Authors:
- USP affiliated authors: PINOTTI, HENRIQUE WALTER - FM ; HEGG, ROBERTO - FM
- Unidade: FM
- Assunto: GINECOLOGIA
- Language: Inglês
- Imprenta:
- Source:
- Título: Revista de Ginecologia e Obstetricia
- Volume/Número/Paginação/Ano: v.5 , n.3 , p.180-9, jul. 1994
-
ABNT
PINOTTI, José Aristodemo et al. Breast cancer control programme in developing countries. Revista de Ginecologia e Obstetricia, v. 5 , n. 3 , p. 180-9, 1994Tradução . . Acesso em: 13 jul. 2025. -
APA
Pinotti, J. A., Barros, A. C. S. D., Hegg, R., & Zeferino, L. C. (1994). Breast cancer control programme in developing countries. Revista de Ginecologia e Obstetricia, 5 ( 3 ), 180-9. -
NLM
Pinotti JA, Barros ACSD, Hegg R, Zeferino LC. Breast cancer control programme in developing countries. Revista de Ginecologia e Obstetricia. 1994 ;5 ( 3 ): 180-9.[citado 2025 jul. 13 ] -
Vancouver
Pinotti JA, Barros ACSD, Hegg R, Zeferino LC. Breast cancer control programme in developing countries. Revista de Ginecologia e Obstetricia. 1994 ;5 ( 3 ): 180-9.[citado 2025 jul. 13 ] - Primary chemotherapy in operable breast cancer: effects on tumoral reduction , extent and complexity of surgical treatment
- Cancer de ovario
- Vias e esquemas de administração dos hormônios esteróides
- Eficácia, tolerabilidade e controle de ciclo de um contraceptivo oral sem estrogênio contendo 30 mcg de levonorgestrel (minipílula)
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)
- Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer
- First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial
- Como diagnosticar e tratar sindrome do climaterio
- Hormonioterapia de reposicao e cancer de mama
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
